- Home
- GPCR vs CVAC Comparison
GPCR vs CVAC Comparison
Compare GPCR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- CVAC
- Stock Information
- Founded
- GPCR 2016
- CVAC 2000
- Country
- GPCR United States
- CVAC Germany
- Employees
- GPCR N/A
- CVAC N/A
- Industry
- GPCR
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- GPCR
- CVAC Health Care
- Exchange
- GPCR Nasdaq
- CVAC Nasdaq
- Market Cap
- GPCR 1.1B
- CVAC 1.2B
- IPO Year
- GPCR 2023
- CVAC 2020
- Fundamental
- Price
- GPCR $20.91
- CVAC $5.34
- Analyst Decision
- GPCR Strong Buy
- CVAC Hold
- Analyst Count
- GPCR 9
- CVAC 3
- Target Price
- GPCR $75.63
- CVAC $6.83
- AVG Volume (30 Days)
- GPCR 1.1M
- CVAC 493.6K
- Earning Date
- GPCR 11-12-2025
- CVAC 11-11-2025
- Dividend Yield
- GPCR N/A
- CVAC N/A
- EPS Growth
- GPCR N/A
- CVAC N/A
- EPS
- GPCR N/A
- CVAC 1.01
- Revenue
- GPCR N/A
- CVAC $599,540,810.00
- Revenue This Year
- GPCR N/A
- CVAC N/A
- Revenue Next Year
- GPCR N/A
- CVAC $24.04
- P/E Ratio
- GPCR N/A
- CVAC $5.31
- Revenue Growth
- GPCR N/A
- CVAC 675.15
- 52 Week Low
- GPCR $13.22
- CVAC $2.37
- 52 Week High
- GPCR $45.37
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- GPCR 58.61
- CVAC 42.37
- Support Level
- GPCR $18.49
- CVAC $5.33
- Resistance Level
- GPCR $22.25
- CVAC $5.41
- Average True Range (ATR)
- GPCR 1.16
- CVAC 0.04
- MACD
- GPCR 0.15
- CVAC -0.01
- Stochastic Oscillator
- GPCR 66.38
- CVAC 15.38
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.